Official Title
Interventional, Open, Non-comparative, Multicenter Study to Assess the Safety and Effectiveness of the Use of the MakAir Artificial Ventilator in the Expected Situation of a Shortage of Technical Devices for Invasive Mechanical Ventilation, Linked to the Coronavirus COVID-19
Brief Summary

The objective of our study is to carry out an evaluation of the safety and the effectiveness of the use of the MakAir respirator as useful supplement in situation of shortage of technical devices of assistance to the mechanical invasive ventilation, related to COVID-19 through a protocol in 3 successive sequences.

Terminated
Acute Respiratory Distress Syndrome

Device: MakAir

MakAir artificial ventilator

Eligibility Criteria

Inclusion Criteria:

Sequence 1 :

- Patient for whom a certificate has been signed by a support person / family member /
close relative independent of the sponsor.

- Adult

- Non-hypoxemic patient (PaO2 / FiO2> 300)

- Patient requiring invasive mechanical ventilation> 24 hours

- Stabilized patient, i.e. not needing an increase in oxygenation for at least 6 hours

Sequence 2 :

- Patient for whom a certificate of consent has been signed by a support person / family
member / close relative independent of the sponsor.

- Adult

- Patient with mild to moderate Acute respiratory distress syndrome (300> Pa02 / FiO2>
100)

- Patient requiring invasive mechanical ventilation> 3 days

- Stabilized patient, i.e. having not required an increase in oxygenation for at least 6
hours

Sequence3 :

- Patient for whom a certificate of consent has been signed by a support person / family
member / close relative independent of the sponsor or waiver due to life-threatening
emergency.

- Adult

- Patient with mild to moderate Acute respiratory distress syndrome (PaO2 / FiO2> 100)
or without Acute respiratory distress syndrome

- Patient requiring invasive mechanical ventilation for any duration

- Situation of shortage among centers investigating technical devices for invasive
ventilation to treat all patients

Exclusion Criteria:

Sequence 1 and sequence 2:

- Patient positive or showing signs of Covid-19 infection

- Tracheotomized patient

- History of pulmonary emphysema or severe to moderate chronic obstructive pulmonary
disease

- Patient in recovery and withdrawal phase of ventilatory assistance

- Pneumothorax or pneumomediastinum

- Hemodynamic instability

- Intracranial hypertension

- Pregnant woman (A urine or blood pregnancy test must be performed for women of
childbearing age)

- Major protected (guardianship, curatorship and under the protection of justice)

- Lack of affiliation to the French social security system

- Participation in another interventional clinical trial

Sequence3 :

- Tracheotomized patient

- History of pulmonary emphysema or severe to moderate moderate chronic obstructive
pulmonary disease

- Patient in recovery and withdrawal phase of ventilatory assistance

- Pneumothorax or pneumomediastinum

- Hemodynamic instability

- Intracranial hypertension

- Pregnant woman (A urine or blood pregnancy test must be performed for women of
childbearing age)

- Major protected (guardianship, curatorship and under the protection of justice)

- Lack of affiliation to the French social security system

- Participation in another interventional clinical trial on mechanical ventilation

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

CHRU Brest
Brest, Finistère, France

CHU Nantes
Nantes, Loire-Atlantique, France

Antoine Roquilly, MD, Study Director
CHU Nantes

Nantes University Hospital
NCT Number
MeSH Terms
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury